{
    "clinical_study": {
        "@rank": "124513", 
        "acronym": "DOVA", 
        "arm_group": [
            {
                "arm_group_label": "15 mg tolvaptan", 
                "arm_group_type": "Active Comparator", 
                "description": "Oral administration of 15 mg tolvaptan on each examination day."
            }, 
            {
                "arm_group_label": "30 mg tolvaptan", 
                "arm_group_type": "Active Comparator", 
                "description": "Oral administration of 30 mg tolvaptan on each examination day."
            }, 
            {
                "arm_group_label": "45 mg tolvaptan", 
                "arm_group_type": "Active Comparator", 
                "description": "Oral administration of 45 mg tolvaptan on each examination day."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Oral administration of a Unikalk tablet"
            }
        ], 
        "brief_summary": {
            "textblock": "Tolvaptan is a selective vasopressin receptor antagonist (V2R) that increases free water and\n      sodium excretion. Inhibition of V2R increases vasopressin concentration in plasma, which\n      stimulates V1-receptors in the vascular bed and may change both central and brachial\n      hemodynamics and plasma concentration of vasoactive hormones.\n\n      The purpose of  the study is to measure the effects of tolvaptan on renal handling of water\n      and sodium, systemic hemodynamics and vasoactive hormones at baseline and during nitric\n      oxide (NO)-inhibition with L-NG-monomethyl-arginine (L-NMMA)."
        }, 
        "brief_title": "Effect of the Diuretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA)", 
        "condition": "Nephropathy", 
        "condition_browse": {
            "mesh_term": "Kidney Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women, age 18-40 years\n\n          -  Body Mass Index (BMI) 18,5-30 kg/m2\n\n        Exclusion Criteria:\n\n          -  Anamnestic or clinical signs of heart, lung, lever, kidney and brain disease\n\n          -  Neoplastic disease\n\n          -  Drug abuse\n\n          -  Alcohol abuse\n\n          -  Medical treatment except peroral anticontraceptive\n\n          -  Pregnancy\n\n          -  Smoking\n\n          -  Abnormal blood and urine sample\n\n          -  Abnormal ECG\n\n          -  Blood donation within a month before examination\n\n          -  Arterial hypertension (>140 mmHg systolic and/or 90 mmHg diastolic)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02078973", 
            "org_study_id": "SAFA-1-2014", 
            "secondary_id": "2013-003800-38"
        }, 
        "intervention": [
            {
                "arm_group_label": "15 mg tolvaptan", 
                "description": "15 mg pr day for 1 day", 
                "intervention_name": "15 mg tolvaptan", 
                "intervention_type": "Drug", 
                "other_name": "Samsca"
            }, 
            {
                "arm_group_label": "30 mg tolvaptan", 
                "description": "30 mg pr day for 1 day", 
                "intervention_name": "30 mg tolvaptan", 
                "intervention_type": "Drug", 
                "other_name": "Samsca"
            }, 
            {
                "arm_group_label": "45 mg tolvaptan", 
                "description": "45 mg pr day for 1 day", 
                "intervention_name": "45 mg tolvaptan", 
                "intervention_type": "Drug", 
                "other_name": "Samsca"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "1 tablet Unikalk pr day for 1 day", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Unikalk"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Nitric Oxide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Tolvaptan", 
            "L-NMMA", 
            "Healthy subjects", 
            "Nephrology"
        ], 
        "lastchanged_date": "March 1, 2014", 
        "location": {
            "contact": {
                "email": "frank.holden.christense@vest.rm.dk", 
                "last_name": "Frank H Mose, MD, PhD", 
                "phone": "+45 78436589"
            }, 
            "facility": {
                "address": {
                    "city": "Holstebro", 
                    "country": "Denmark", 
                    "zip": "7500"
                }, 
                "name": "Department of medical research"
            }, 
            "investigator": {
                "last_name": "Safa Therwani, MB", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "4", 
        "official_title": "The Effects of Tolvaptan on Renal Handling of Water and Sodium, Vasoactive Hormones and Circulatory System, During Basal Conditions and During Inhibition of the Nitric Oxide System in Healthy Subjects. A Dose-response Study.", 
        "overall_contact": {
            "email": "safatherwani@hotmail.com", 
            "last_name": "Safa Therwani, MB", 
            "phone": "+45 31515473"
        }, 
        "overall_contact_backup": {
            "email": "frank.holden.christense@vest.rm.dk", 
            "last_name": "Frank H. Mose H Mose, MD, PhD", 
            "phone": "+45 78436589"
        }, 
        "overall_official": {
            "affiliation": "Department of medical research", 
            "last_name": "Frank H Mose, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Denmark: Danish Medicines Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Measurement of H2O clearance at baseline, during and after L-NMMA infusion", 
            "measure": "CH2O", 
            "safety_issue": "No", 
            "time_frame": "5-6 Hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02078973"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Regional Hospital Holstebro", 
            "investigator_full_name": "Erling Bjerregaard Pedersen", 
            "investigator_title": "Professor, MD, Dr.Sci.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Urine biomarkers(Aquaporins and Epithelial Sodium Channels \u03b3)", 
                "safety_issue": "No", 
                "time_frame": "5-6 Hours"
            }, 
            {
                "measure": "Central and brachial blood pressure", 
                "safety_issue": "No", 
                "time_frame": "5-6 Hours"
            }, 
            {
                "measure": "Augmentation Index", 
                "safety_issue": "No", 
                "time_frame": "5-6 Hours"
            }, 
            {
                "measure": "Vasoactive Hormones( Angiotensin II, Aldosterone, Endothelin, Atrial Natriuretic Peptide, Brain Natriuretic Peptide, Arginin Vasopressin)", 
                "safety_issue": "No", 
                "time_frame": "5-6 Hours"
            }, 
            {
                "description": "Measurement of Sodium excretion at baseline, during and after L-NMMA infusion.", 
                "measure": "Fractional sodium excretion", 
                "safety_issue": "No", 
                "time_frame": "5-6 Hours"
            }
        ], 
        "source": "Regional Hospital Holstebro", 
        "sponsors": {
            "collaborator": {
                "agency": "Aarhus University Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Regional Hospital Holstebro", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}